当前位置: X-MOL 学术Stroke › 论文详情
Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo.
Stroke ( IF 6.046 ) Pub Date : 2020-02-27 , DOI: 10.1161/strokeaha.119.027476
Shashank Agarwal,Erica Scher,Aaron Lord,Jennifer Frontera,Koto Ishida,Jose Torres,Sara Rostanski,Eva Mistry,Brian Mac Grory,Shawna Cutting,Tina Burton,Brian Silver,Ava L Liberman,Mackenzie P Lerario,Karen Furie,James Grotta,Pooja Khatri,Jeffrey Saver,Shadi Yaghi

Background and Purpose- The first of the 2 NINDS (National Institute of Neurological Disorders and Stroke) Study trials did not show a significant increase in early neurological improvement, defined as National Institutes of Health Stroke Scale (NIHSS) improvement by ≥4, with alteplase treatment. We hypothesized that early neurological improvement defined as a percentage change in NIHSS (percent change NIHSS) at 24 hours is superior to other definitions in predicting 3-month functional outcomes and using this definition there would be treatment benefit of alteplase over placebo at 24 hours. Methods- We analyzed the NINDS rt-PA Stroke Study (Parts 1 and 2) trial data. Percent change NIHSS was defined as ([admission NIHSS score-24-hour NIHSS score]×100/admission NIHSS score] and delta NIHSS as (admission NIHSS score-24-hour NIHSS score). We compared early neurological improvement using these definitions between alteplase versus placebo patients. We also used receiver operating characteristic curve to determine the predictive association of early neurological improvement with excellent 3-month functional outcomes (Barthel Index score of 95-100 and modified Rankin Scale score of 0-1), good 3-month functional outcome (modified Rankin Scale score of 0-2), and 3-month infarct volume. Results- There was a significantly greater improvement in the 24-hour median percent change NIHSS among patients treated with alteplase compared with the placebo group (28% versus 15%; P=0.045) but not median delta NIHSS (3 versus 2; P=0.471). Receiver operating characteristic curve comparison showed that percent change NIHSS (ROCpercent) was better than delta NIHSS (ROCdelta) and admission NIHSS (ROCadmission) with regards to excellent 3-month Barthel Index (ROCpercent, 0.83; ROCdelta, 0.76; ROCadmission, 0.75), excellent 3-month modified Rankin Scale (ROCpercent, 0.83; ROCdelta, 0.74; ROCadmission, 0.78), and good 3-month modified Rankin Scale (ROCpercent, 0.83; ROCdelta, 0.76; ROCadmission, 0.78). Conclusions- In the NINDS rt-PA trial, alteplase was associated with a significant percent change improvement in NIHSS at 24 hours. Percent change in NIHSS may be a better surrogate marker of thrombolytic activity and 3-month outcomes.
更新日期:2020-02-27

 

全部期刊列表>>
聚焦商业经济政治法律
智控未来
控制与机器人
化学研究精选
欢迎探索2019年最具下载量的地球科学论文
招募海内外科研人才,上自然官网
基因组学对精准公共卫生的影响,专辑征稿
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
x-mol收录
湖南大学化学化工学院刘松
上海有机所
李旸
大连化物所
香港大学
X-MOL
支志明
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug